Benain Jean-Philippe, Faller Bernadette, Briat Claude, Jacquelinet Christian, Brami Michèle, Aoustin Martine, Dubois Jean-Pierre, Rieu Philippe, Behaghel Cecile, Duru Gérard
JNB-Développement, 6, rue du Général-Larminat, 75015 Paris, France.
Nephrol Ther. 2007 Jun;3(3):96-106. doi: 10.1016/j.nephro.2007.03.001. Epub 2007 May 11.
The provision of care for patients with end-stage chronic renal failure is an important medical and economic challenge for the Health Insurance. Previous studies have shown a lower cost for home dialysis. More recently, studies have confirmed identical short-term survival rates between haemodialysis and peritoneal dialysis. Notwithstanding, home dialysis techniques utilization remains weak in France. This work aims at: determining the average annual cost of dialysis, per patient and per technique of dialysis, and assessing the global annual cost of dialysis in France, from the Health Insurance perspective. Methodologically, this article provides a static estimation of the cost of dialysis. Costs related to co-morbidities of end-stage chronic renal failure have not been considered. Standard patient care schemes have been outlined by a multidisciplinary expert committee, for each dialysis technique, and have been valorised using publicly available data and tariffs recorded in 2005. Our result show that home dialysis techniques are the less costly, with an average annual cost per patient of 49.9, 49.7 and 50.0 k euro respectively for home haemodialysis, automated peritoneal dialysis, and continuous ambulatory peritoneal dialysis. Autodialysis, autonomous in-center haemodialysis and in-center haemodialysis respectively cost 59.5, 62.3 and 81.5 k euro per patient and per annum. The total 2005 cost of dialysis for the Health Insurance is estimated at 2.1 billion euro. Therefore, the development of alternative techniques to in-center haemodialysis, such as home dialysis or autonomous in-center haemodialysis, autodialysis being already well developed, could generate savings for the Health Insurance. From the patient's perspective, it could also allow the enlightened choice of the best customized technique, less guided by local offer than by medical or social criteria, as well as by the patient's own opinion.
为终末期慢性肾衰竭患者提供护理,对医疗保险来说是一项重大的医疗和经济挑战。此前的研究表明,家庭透析成本较低。最近,研究证实血液透析和腹膜透析的短期生存率相同。尽管如此,家庭透析技术在法国的利用率仍然很低。这项工作旨在:从医疗保险的角度,确定每位患者每种透析技术的平均年度透析成本,并评估法国透析的全球年度成本。在方法上,本文提供了透析成本的静态估计。未考虑终末期慢性肾衰竭合并症的相关成本。一个多学科专家委员会针对每种透析技术制定了标准患者护理方案,并使用2005年记录的公开可用数据和收费标准进行了评估。我们的结果表明,家庭透析技术成本较低,家庭血液透析、自动化腹膜透析和持续性非卧床腹膜透析每位患者的平均年度成本分别为49.9、49.7和50.0千欧元。自我透析、自主中心血液透析和中心血液透析每位患者每年的成本分别为59.5、62.3和81.5千欧元。2005年医疗保险的透析总成本估计为21亿欧元。因此,开发中心血液透析的替代技术,如家庭透析或自主中心血液透析(自我透析已经得到充分发展),可为医疗保险节省开支。从患者的角度来看,这也可以让患者根据医学或社会标准以及自己的意见,更明智地选择最适合自己的技术,而较少受到当地医疗服务的限制。